Clinical Trial Update: Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update examines the efficacy of imatinib in patients with intermediate-risk gastrointestinal stromal tumor who have a high-risk genomic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Assistance Publique Hopitaux De Marseille | Conditions: Gastrointestinal Stromal Tumor | Phase 3 | Status: UNKNOWN